Chemo-Pharma [CPL] vs Nippon Life India [NAM] Detailed Stock Comparison
Chemo-Pharma
BSE
Loading...
Nippon Life India
BSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Chemo-Pharma wins in 14 metrics, Nippon Life India wins in 5 metrics, with 0 ties. Chemo-Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Chemo-Pharma | Nippon Life India | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.17 | 211.11 | Chemo-Pharma |
| Price-to-Book Ratio | 2.56 | 4.52 | Chemo-Pharma |
| Debt-to-Equity Ratio | 44.70 | 0.00 | Nippon Life India |
| PEG Ratio | 0.62 | -5.03 | Nippon Life India |
| EV/EBITDA | 13.74 | 69.78 | Chemo-Pharma |
| Profit Margin (TTM) | 11.11% | 0.49% | Chemo-Pharma |
| Operating Margin (TTM) | 9.62% | 1.65% | Chemo-Pharma |
| EBITDA Margin (TTM) | 9.62% | 1.65% | Chemo-Pharma |
| Return on Equity | 20.97% | 3.14% | Chemo-Pharma |
| Return on Assets (TTM) | 11.26% | 3.01% | Chemo-Pharma |
| Free Cash Flow (TTM) | $41.66M | $-8.13M | Chemo-Pharma |
| 1-Year Return | -14.20% | -47.22% | Chemo-Pharma |
| Price-to-Sales Ratio (TTM) | 1.42 | 1.05 | Nippon Life India |
| Enterprise Value | $4.61B | $447.38M | Chemo-Pharma |
| EV/Revenue Ratio | 1.58 | 0.92 | Nippon Life India |
| Gross Profit Margin (TTM) | 29.30% | 4.58% | Chemo-Pharma |
| Revenue per Share (TTM) | $51 | $90 | Nippon Life India |
| Earnings per Share (Diluted) | $5.66 | $0.45 | Chemo-Pharma |
| Beta (Stock Volatility) | 0.22 | 0.77 | Chemo-Pharma |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Chemo-Pharma vs Nippon Life India Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Chemo-Pharma | -0.47% | -1.88% | -7.83% | -14.89% | -23.12% | -41.76% |
| Nippon Life India | 0.09% | -3.69% | -2.06% | 14.46% | 0.00% | -31.65% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Chemo-Pharma | -14.20% | 314.25% | 117.43% | 728.00% | 1,222.85% | 1,222.85% |
| Nippon Life India | -47.22% | 63.79% | 189.63% | 423.42% | 467.16% | 467.16% |
Performance & Financial Health Analysis: Chemo-Pharma vs Nippon Life India
| Metric | CPL | NAM |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.13B | ₹512.24M |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 37,361 | 150 |
| 90 Day Avg. Volume | 36,863 | 161 |
| Last Close | ₹67.73 | ₹95.00 |
| 52 Week Range | ₹61.40 - ₹128.00 | ₹68.64 - ₹198.00 |
| % from 52W High | -47.09% | -52.02% |
| All-Time High | ₹128.00 (Jan 06, 2025) | ₹198.00 (Sep 02, 2024) |
| % from All-Time High | -47.09% | -52.02% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | -0.60% |
| Quarterly Earnings Growth | 0.34% | -0.43% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.00% |
| Operating Margin (TTM) | 0.10% | 0.02% |
| Return on Equity (TTM) | 0.21% | 0.03% |
| Debt to Equity (MRQ) | 44.70 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹26.86 | ₹21.01 |
| Cash per Share (MRQ) | ₹1.01 | ₹11.69 |
| Operating Cash Flow (TTM) | ₹277.99M | ₹16.34M |
| Levered Free Cash Flow (TTM) | ₹313.23M | ₹3.57M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Chemo-Pharma vs Nippon Life India
| Metric | CPL | NAM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.17 | 211.11 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.62 | -5.03 |
| Price to Sales (TTM) | 1.42 | 1.05 |
| Price to Book (MRQ) | 2.56 | 4.52 |
| Market Capitalization | ||
| Market Capitalization | ₹4.13B | ₹512.24M |
| Enterprise Value | ₹4.61B | ₹447.38M |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.58 | 0.92 |
| Enterprise to EBITDA | 13.74 | 69.78 |
| Risk & Other Metrics | ||
| Beta | 0.22 | 0.77 |
| Book Value per Share (MRQ) | ₹26.86 | ₹21.01 |
Financial Statements Comparison: Chemo-Pharma vs Nippon Life India
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CPL | NAM |
|---|---|---|
| Revenue/Sales | ₹697.42M | ₹118.41M |
| Cost of Goods Sold | ₹493.08M | ₹112.98M |
| Gross Profit | ₹204.34M | ₹5.43M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹67.12M | ₹1.70M |
| EBITDA | ₹79.31M | ₹2.34M |
| Pre-Tax Income | ₹55.13M | ₹1.96M |
| Income Tax | ₹12.13M | ₹400,000 |
| Net Income (Profit) | ₹42.99M | ₹1.56M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CPL | NAM |
|---|---|---|
| Cash & Equivalents | ₹12.05M | ₹1.50M |
| Total Current Assets | ₹2.51B | ₹94.28M |
| Total Current Liabilities | ₹1.17B | ₹3.96M |
| Long-Term Debt | ₹109.50M | ₹0 |
| Total Shareholders Equity | ₹1.49B | ₹113.51M |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹144.04M | ₹24.14M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CPL | NAM |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CPL | NAM |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 37,361 | 150 |
| Average Daily Volume (90 Day) | 36,863 | 161 |
| Shares Outstanding | 57.55M | 5.39M |
| Float Shares | 17.06M | 482,054 |
| % Held by Insiders | 0.70% | 0.87% |
| % Held by Institutions | 0.00% | 0.00% |
Dividend Analysis & Yield Comparison: Chemo-Pharma vs Nippon Life India
| Metric | CPL | NAM |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |